{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:56Z","timestamp":1791484376488,"version":"4.3.4"},"reference-count":53,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                    <jats:p>All US Food and Drug Administration-approved medications for Tourette syndrome are antipsychotics, and their use is limited by the risk of weight gain, metabolic changes, and drug-induced movement disorders. Several small trials suggest that ecopipam, a first-in-class, selective dopamine 1 receptor antagonist, reduces tics with a low risk for these adverse events. This trial sought to further evaluate the efficacy, safety, and tolerability of ecopipam in children and adolescents with moderate to severe Tourette syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This was a multicenter, randomized, double-blind, placebo-controlled, phase 2b trial. Subjects aged \u22656 to &amp;lt;18 years with a baseline Yale Global Tic Severity Score Total Tic Score of \u226520 were randomly assigned 1:1 to ecopipam (n = 76) or placebo (n = 77). The primary endpoint was mean change over 12 weeks in the Yale Global Tic Severity Score Total Tic Score. The Clinical Global Impression of Tourette Syndrome Severity was the secondary endpoint. Safety and tolerability were evaluated at each study visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Total tic scores were significantly reduced from baseline to 12 weeks in the ecopipam group compared with placebo (least squares mean differences \u22123.44, 95% confidence interval \u22126.09 to \u22120.79, P = .01). Improvement in Clinical Global Impression of Tourette Syndrome Severity was also greater in the ecopipam group (P = .03). More weight gain was seen in subjects assigned to placebo. No metabolic or electrocardiogram changes were identified. Headache (15.8%), insomnia (14.5%), fatigue (7.9%), and somnolence (7.9%) were the most common adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Among children and adolescents with TS, ecopipam reduces tics to a greater extent than placebo, without observable evidence of common antipsychotic-associated side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2022-059574","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T11:23:46Z","timestamp":1673954626000},"source":"Crossref","is-referenced-by-count":42,"title":["Ecopipam for Tourette Syndrome: A Randomized Trial"],"prefix":"10.1542","volume":"151","author":[{"given":"Donald L.","family":"Gilbert","sequence":"first","affiliation":[{"name":"aDivision of Neurology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"},{"name":"bDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Dubow","sequence":"additional","affiliation":[{"name":"cClintrex Research Corporation, Sarasota, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Cunniff","sequence":"additional","affiliation":[{"name":"dParagon Biosciences, LLC., Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Wanaski","sequence":"additional","affiliation":[{"name":"dParagon Biosciences, LLC., Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"eERG Clinical, Berkeley Heights, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul R.","family":"Mahableshwarkar","sequence":"additional","affiliation":[{"name":"fEmalex Biosciences, Inc., Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2023111013554753200_B1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR","author":"American Psychiatric Association","year":"2022","edition":"5th edition"},{"key":"2023111013554753200_B2","doi-asserted-by":"crossref","first-page":"16097","DOI":"10.1038\/nrdp.2016.97","article-title":"Gilles de la Tourette syndrome","volume":"3","author":"Robertson","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"2023111013554753200_B3","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/mds.26766","article-title":"The prevalence of diagnosed tourette syndrome in Canada: a national population-based study","volume":"31","author":"Yang","year":"2016","journal-title":"Mov Disord"},{"issue":"2","key":"2023111013554753200_B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mds.26089","article-title":"Population prevalence of Tourette syndrome: a systematic review and meta-analysis","volume":"30","author":"Scharf","year":"2015","journal-title":"Mov Disord"},{"issue":"2","key":"2023111013554753200_B5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40474-021-00231-3","article-title":"Course of tic disorders over the lifespan","volume":"8","author":"Black","year":"2021","journal-title":"Curr Dev Disord Rep"},{"issue":"1","key":"2023111013554753200_B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10578-020-01111-4","article-title":"Academic, interpersonal, recreational, and family impairment in children with Tourette syndrome and attention-deficit\/hyperactivity disorder","volume":"53","author":"Ricketts","year":"2022","journal-title":"Child Psychiatry Hum Dev"},{"key":"2023111013554753200_B7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jpsychires.2020.12.040","article-title":"Defining tic severity and tic impairment in Tourette disorder","volume":"133","author":"McGuire","year":"2021","journal-title":"J Psychiatr Res"},{"issue":"4","key":"2023111013554753200_B8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/0883073820967518","article-title":"Implementation of the Mini-Child Tourette Syndrome Impairment Scale: relationships to symptom severity and treatment decisions","volume":"36","author":"Garris","year":"2021","journal-title":"J Child Neurol"},{"issue":"2","key":"2023111013554753200_B9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10578-010-0211-4","article-title":"Exploring the impact of chronic tic disorders on youth: results from the Tourette Syndrome Impact Survey","volume":"42","author":"Conelea","year":"2011","journal-title":"Child Psychiatry Hum Dev"},{"issue":"1","key":"2023111013554753200_B10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10578-011-0249-y","article-title":"Peer victimization in youth with Tourette syndrome and other chronic tic disorders","volume":"43","author":"Zinner","year":"2012","journal-title":"Child Psychiatry Hum Dev"},{"issue":"5","key":"2023111013554753200_B11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2022.0167","article-title":"Association of Tourette syndrome and chronic tic disorder with violent assault and criminal convictions","volume":"79","author":"Mataix-Cols","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"2023111013554753200_B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.biopsych.2020.09.014","article-title":"Association of Tourette syndrome and chronic tic disorder with subsequent risk of alcohol- or drug- related disorders, criminal convictions, and death: a population-based family study","volume":"89","author":"Virtanen","year":"2021","journal-title":"Biol Psychiatry"},{"issue":"10","key":"2023111013554753200_B13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaneurol.2021.2798","article-title":"Association of Tourette syndrome and chronic tic disorder with cervical spine disorders and related neurological complications","volume":"78","author":"Isung","year":"2021","journal-title":"JAMA Neurol"},{"key":"2023111013554753200_B14","first-page":"163","article-title":"The pharmacological treatment of Tourette syndrome","volume-title":"International Review of Movement Disorders","author":"Baizabal-Carvallo","year":"2022"},{"issue":"2","key":"2023111013554753200_B15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/cap.2018.0092","article-title":"Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting","volume":"29","author":"Pozzi","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"2023111013554753200_B16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pediatrneurol.2009.04.002","article-title":"Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome","volume":"41","author":"Degrauw","year":"2009","journal-title":"Pediatr Neurol"},{"issue":"19","key":"2023111013554753200_B17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"2023111013554753200_B18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1212\/WNL.0000000000003710","article-title":"Moderators and predictors of response to behavior therapy for tics in Tourette syndrome","volume":"88","author":"Sukhodolsky","year":"2017","journal-title":"Neurology"},{"key":"2023111013554753200_B19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5334\/tohm.442","article-title":"Merging the pathophysiology and pharmacotherapy of tics","volume":"8","author":"Augustine","year":"2019","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"2023111013554753200_B20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.biopsych.2018.02.1172","article-title":"Dopaminergic disturbances in Tourette syndrome: an integrative account","volume":"84","author":"Maia","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"6477","key":"2023111013554753200_B21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.aaz5751","article-title":"Local D2- to D1-neuron transmodulation updates goal-directed learning in the striatum","volume":"367","author":"Matamales","year":"2020","journal-title":"Science"},{"issue":"5","key":"2023111013554753200_B22","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/jnc.15340","article-title":"Neurochemical mechanisms and neurocircuitry underlying the contribution of stress to cocaine seeking","volume":"157","author":"Caccamise","year":"2021","journal-title":"J Neurochem"},{"issue":"10","key":"2023111013554753200_B23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0006-3223(95)00596-X","article-title":"Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette\u2019s syndrome","volume":"40","author":"Sallee","year":"1996","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2023111013554753200_B24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/cap.2016.0026","article-title":"Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents","volume":"27","author":"Sallee","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"2023111013554753200_B25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"key":"2023111013554753200_B26","doi-asserted-by":"crossref","first-page":"623681","DOI":"10.3389\/fpsyt.2021.623681","article-title":"The burden of antipsychotic-induced weight gain and metabolic syndrome in children","volume":"12","author":"Libowitz","year":"2021","journal-title":"Front Psychiatry"},{"issue":"1","key":"2023111013554753200_B27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","article-title":"A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome","volume":"37","author":"Gilbert","year":"2014","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"2023111013554753200_B28","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","article-title":"Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study","volume":"33","author":"Gilbert","year":"2018","journal-title":"Mov Disord"},{"issue":"4","key":"2023111013554753200_B29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","article-title":"The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity","volume":"28","author":"Leckman","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2023111013554753200_B30","first-page":"550","article-title":"Clinical assessment of tic disorder severity","volume-title":"Tourette\u2019s Syndrome and Tic Disorders","author":"Leckman","year":"1988"},{"issue":"1","key":"2023111013554753200_B31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","article-title":"Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy","volume":"19","author":"Staunton","year":"2021","journal-title":"Health Qual Life Outcomes"},{"issue":"18","key":"2023111013554753200_B32","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1212\/01.wnl.0000327890.02893.61","article-title":"The Gilles de la Tourette syndrome- quality of life scale (GTS-QOL): development and validation","volume":"71","author":"Cavanna","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"2023111013554753200_B33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0883073816670083","article-title":"The English version of the Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL","volume":"32","author":"Su","year":"2017","journal-title":"J Child Neurol"},{"issue":"2","key":"2023111013554753200_B34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cct.2013.08.012","article-title":"Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods","volume":"36","author":"Jeon","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"12","key":"2023111013554753200_B35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2023111013554753200_B36","first-page":"218","article-title":"Clinical global impression scale","volume":"338","author":"Guy","year":"1976","journal-title":"ECDEU Assess Man Psychopharm-Rev"},{"key":"2023111013554753200_B37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug- induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"8","key":"2023111013554753200_B38","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1007\/s10826-014-0038-x","article-title":"The Children\u2019s Depression Inventory in worldwide child development research: A reliability generalization study","volume":"24","author":"Sun","year":"2015","journal-title":"J Child Fam Stud"},{"issue":"6","key":"2023111013554753200_B39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"2023111013554753200_B40","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00004583-200209000-00006","article-title":"The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties","volume":"41","author":"Research Units on Pediatric Psychopharmacology Anxiety Study Group","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2023111013554753200_B41","volume-title":"The Swanson, Nolan, and Pelham Teacher and Parent Rating Scale (SNAP-IV)","author":"Swanson","year":"1995"},{"issue":"9","key":"2023111013554753200_B42","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/cap.2017.0024","article-title":"Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders","volume":"27","author":"Murphy","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"2023111013554753200_B43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","author":"Tourette\u2019s Syndrome Study Group","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"2023111013554753200_B44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","article-title":"Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial","volume":"43","author":"Gilbert","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"08","key":"2023111013554753200_B45","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.4088\/JCP.12m08189","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder","volume":"74","author":"Yoo","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2023111013554753200_B46","first-page":"1093","article-title":"Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity","volume":"247","author":"Chipkin","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2023111013554753200_B47","first-page":"42","article-title":"In vivo binding of SCH 39166: a D-1 selective antagonist","volume":"257","author":"McQuade","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2023111013554753200_B48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02246068","article-title":"Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"2023111013554753200_B49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s002130100724","article-title":"Repeated administration of the D1\/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine","volume":"155","author":"Nann-Vernotica","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"2023111013554753200_B50","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity (Silver Spring)"},{"issue":"13","key":"2023111013554753200_B51","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/bph.13243","article-title":"The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement","volume":"173","author":"Godar","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2023111013554753200_B52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.mp.4001144","article-title":"A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry","volume":"7","author":"Nordstrom","year":"2002","journal-title":"Molec Psych"},{"key":"2023111013554753200_B53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbr.2015.11.028","article-title":"The dopamine D1 receptor agonist SKF-82958 effectively increases eye blinking count in common marmosets","volume":"300","author":"Kotani","year":"2016","journal-title":"Behav Brain Res"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-059574\/1564723\/peds_2022059574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-059574\/1564723\/peds_2022059574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:57:27Z","timestamp":1699606647000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/151\/2\/e2022059574\/190459\/Ecopipam-for-Tourette-Syndrome-A-Randomized-Trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,11]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-059574","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742490240.793597587","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"article-number":"e2022059574"}}